CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue	$ 8,707,310	$ 5,191,629
Cost of revenue	2,384,842	1,738,589
Gross margin	6,322,468	3,453,040
Other expenses:
Research and development	1,965,286	2,418,633
Legal, financial and other consulting	519,002	561,516
Selling, general and administrative	6,316,934	4,758,084
Total expenses	8,801,222	7,738,233
Loss from operations	(2,478,754)	(4,285,193)
Other expense:
Interest expense, net	(305,537)	(205,179)
Loss on foreign currency transactions	(668,488)	(393,455)
Total other expense, net	(974,025)	(598,634)
Loss before benefit from income taxes	(3,452,779)	(4,883,827)
Benefit from income taxes	0	0
Net loss attributable to common shareholders	$ (3,452,779)	$ (4,883,827)
Basic and diluted net loss per common share	$ (0.10)	$ (0.15)
Weighted average number of shares of common stock outstanding	33,981,262	31,931,215
Net loss	$ (3,452,779)	$ (4,883,827)
Other comprehensive income (loss):
Currency translation adjustment	609,828	306,287
Comprehensive loss	(2,842,951)	(4,577,540)
Product
Revenue:
Total revenue	8,155,969	4,576,579
Cyto Sorb Sales
Revenue:
Total revenue	8,155,969	4,509,779
Other Sales
Revenue:
Total revenue	0	66,800
Grant
Revenue:
Total revenue	$ 551,341	$ 615,050